Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 May 18. doi: 10.1093/neuonc/noy056. [Epub ahead of print]

PMID:
29788429
2.

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Kurz SC, Wen PY.

Curr Treat Options Neurol. 2018 Apr 18;20(5):14. doi: 10.1007/s11940-018-0499-0. Review.

PMID:
29666934
3.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT.

Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6.

4.

Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy053. [Epub ahead of print]

PMID:
29660006
5.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy054. [Epub ahead of print]

PMID:
29660005
6.

Toward methylation-based classification of central nervous system tumors.

Hegi ME, Kleihues P, Wen PY, SuvĂ  ML.

Neuro Oncol. 2018 Apr 9;20(5):579-581. doi: 10.1093/neuonc/noy023. No abstract available.

PMID:
29584921
7.

Imaging Criteria in Neuro-oncology.

Nowosielski M, Wen PY.

Semin Neurol. 2018 Feb;38(1):24-31. doi: 10.1055/s-0038-1627468. Epub 2018 Mar 16.

PMID:
29548049
8.

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.

Neuro Oncol. 2018 Mar 6. doi: 10.1093/neuonc/noy027. [Epub ahead of print]

PMID:
29518210
9.

Imaging in neuro-oncology.

Nandu H, Wen PY, Huang RY.

Ther Adv Neurol Disord. 2018 Feb 28;11:1756286418759865. doi: 10.1177/1756286418759865. eCollection 2018. Review.

10.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
11.

Reflective Amplification without Population Inversion from a Strongly Driven Superconducting Qubit.

Wen PY, Kockum AF, Ian H, Chen JC, Nori F, Hoi IC.

Phys Rev Lett. 2018 Feb 9;120(6):063603. doi: 10.1103/PhysRevLett.120.063603.

PMID:
29481213
12.

Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.

Zhou M, Zhou Y, Liao H, Rowland BC, Kong X, Arvold ND, Reardon DA, Wen PY, Lin AP, Huang RY.

Neuro Oncol. 2018 Feb 9. doi: 10.1093/neuonc/noy022. [Epub ahead of print]

PMID:
29438510
13.

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.

Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA.

Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3.

PMID:
29398153
14.

Antiangiogenic Therapy of High-Grade Gliomas.

Jo J, Wen PY.

Prog Neurol Surg. 2018;31:180-199. doi: 10.1159/000467379. Epub 2018 Jan 25.

PMID:
29393186
15.

The siren song of bevacizumab: swan song or clarion call?

Schiff D, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):147-148. doi: 10.1093/neuonc/nox244. No abstract available.

PMID:
29365205
16.

Meeting Update-Society for Neuro-Oncology 2017 Annual Meeting.

Strowd RE, Kim AH, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):156-159. doi: 10.1093/neuonc/nox239. No abstract available.

PMID:
29365203
17.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
18.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
19.

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) Resource in Neuro-Oncology.

Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM.

Neuro Oncol. 2017 Dec 23. doi: 10.1093/neuonc/nox242. [Epub ahead of print]

PMID:
29294069
20.

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY.

Cancer. 2018 Apr 1;124(7):1438-1448. doi: 10.1002/cncr.31172. Epub 2017 Dec 19.

PMID:
29266174
21.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT.

NPJ Precis Oncol. 2017;1. pii: 20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12.

22.

2016 World Health Organization Classification of Central Nervous System Tumors.

Wen PY, Huse JT.

Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1531-1547. doi: 10.1212/CON.0000000000000536.

PMID:
29200109
23.

Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging.

Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J.

Clin Cancer Res. 2018 Mar 1;24(5):1073-1081. doi: 10.1158/1078-0432.CCR-17-2236. Epub 2017 Nov 22.

PMID:
29167275
24.

Transition: Message from the Editor-in-Chief.

Wen PY.

Neuro Oncol. 2017 Nov 29;19(12):1567. doi: 10.1093/neuonc/nox201. No abstract available.

PMID:
29145623
25.

Radiographic prediction of meningioma grade by semantic and radiomic features.

Coroller TP, Bi WL, Huynh E, Abedalthagafi M, Aizer AA, Greenwald NF, Parmar C, Narayan V, Wu WW, Miranda de Moura S, Gupta S, Beroukhim R, Wen PY, Al-Mefty O, Dunn IF, Santagata S, Alexander BM, Huang RY, Aerts HJWL.

PLoS One. 2017 Nov 16;12(11):e0187908. doi: 10.1371/journal.pone.0187908. eCollection 2017.

26.

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP.

Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209.

PMID:
29126203
27.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J 3rd, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A.

J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.

PMID:
29118226
28.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT.

Oncotarget. 2017 May 12;8(45):79298-79304. doi: 10.18632/oncotarget.17837. eCollection 2017 Oct 3.

29.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
30.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

31.

Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Ellingson BM, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Mar 27;20(4):457-471. doi: 10.1093/neuonc/nox193.

PMID:
29040703
32.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):259-267. doi: 10.1093/neuonc/nox151.

33.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.

Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154.

34.

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.

Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen PY, Chiocca EA, Lawler SE.

Neuro Oncol. 2018 Jan 22;20(2):225-235. doi: 10.1093/neuonc/nox139.

PMID:
29016938
35.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

PMID:
29016887
36.

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.

Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.

J Neurooncol. 2017 Dec;135(3):581-591. doi: 10.1007/s11060-017-2611-9. Epub 2017 Oct 3.

PMID:
28975467
37.

Adjuvant treatments for ependymomas.

Sartor EA, Wen PY.

J Neurosurg Sci. 2018 Feb;62(1):71-77. doi: 10.23736/S0390-5616.17.04211-4. Epub 2017 Sep 22.

38.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

PMID:
28814435
39.

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF.

Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.

PMID:
28655794
40.

Response Assessment in Neuro-Oncology Clinical Trials.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ.

J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. Review.

PMID:
28640707
41.

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL.

Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092.

PMID:
28499022
42.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

43.

Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee.

Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW.

Neuro Oncol. 2018 Jan 10;20(1):13-23. doi: 10.1093/neuonc/nox087.

PMID:
28449033
44.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA.

Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077.

PMID:
28444227
45.

Angiogenesis inhibitors in tackling recurrent glioblastoma.

Hundsberger T, Reardon DA, Wen PY.

Expert Rev Anticancer Ther. 2017 Jun;17(6):507-515. doi: 10.1080/14737140.2017.1322903. Epub 2017 May 2. Review.

PMID:
28438066
46.

How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.

Wen PY, Jiang T, Schiff D.

Neuro Oncol. 2017 Apr 1;19(4):459-460. doi: 10.1093/neuonc/nox041. No abstract available.

47.

Immunomodulation for glioblastoma.

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH.

Curr Opin Neurol. 2017 Jun;30(3):361-369. doi: 10.1097/WCO.0000000000000451. Review.

PMID:
28368867
48.

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM.

Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.

PMID:
28339723
49.

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S.

Neuro Oncol. 2017 May 1;19(5):614-624. doi: 10.1093/neuonc/now277. Review.

50.

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

JAMA Oncol. 2017 Aug 1;3(8):1069-1077. doi: 10.1001/jamaoncol.2017.0001.

Supplemental Content

Support Center